P/E at 35.4 vs Industry's 37.05: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount in a High-P/E Sector

The pharmaceutical sector currently trades at an average P/E of 37.05, reflecting elevated investor expectations amid ongoing innovation and regulatory approvals. Against this backdrop, Sun Pharmaceutical Industries Ltd’s P/E of 35.4 represents a 4.5% discount to the sector average. This valuation gap is relatively narrow but noteworthy given the company’s large-cap status and market leadership. The premium or discount relative to peers often signals market sentiment about growth prospects and risk profile — Sun Pharma’s slight discount may reflect cautious optimism or recent performance concerns.

Performance Across Timeframes: Divergent Momentum Signals

Examining returns over multiple horizons reveals a complex performance narrative. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 14.72% gain, significantly outperforming the Sensex’s 8.94% loss. This outperformance extends to the three-month period, where the stock rose 2.91% compared to the Sensex’s modest 0.57% gain. However, the short-term trend is less encouraging: the stock has declined 2.76% over the past week and 4.82% in the last month, slightly underperforming the Sensex’s respective falls of 2.95% and 4.99%. The recent four-day consecutive fall, resulting in a 2.94% drop, underscores this short-term weakness — is this a temporary correction or a sign of deeper momentum erosion?

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd presents a nuanced picture. The stock currently trades above its 200-day moving average, a long-term bullish indicator suggesting underlying strength. However, it remains below its 5-day, 20-day, 50-day, and 100-day moving averages, signalling short- to medium-term pressure. This configuration often points to a recent bounce within a broader downtrend or consolidation phase. The 200 DMA support may act as a floor, but the inability to reclaim shorter-term averages raises questions about the sustainability of any recovery — is this a genuine recovery or a dead-cat bounce?

Relative Performance Versus Sensex: Consistent Outperformance Over Medium Term

Over longer horizons, Sun Pharmaceutical Industries Ltd has consistently outpaced the Sensex. The three-year return stands at 62.39%, compared to the Sensex’s 10.62%, while the five-year gain of 137.83% dwarfs the Sensex’s 27.36%. Even year-to-date, the stock has risen 7.37% while the Sensex declined 12.87%. However, the ten-year comparison is less favourable, with the stock’s 131.64% return lagging the Sensex’s 157.86%. This divergence may reflect sector-specific cycles or company-specific challenges over the last decade. The data suggests that while Sun Pharma has been a strong medium-term performer, it has not matched the broader market’s long-term growth.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen varied results in recent earnings seasons. Of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 negative. This distribution indicates a sector grappling with both growth opportunities and headwinds such as regulatory scrutiny and pricing pressures. Sun Pharmaceutical Industries Ltd operates within this mixed environment, which may explain some of the volatility in its short-term performance and valuation discount relative to peers.

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 67.0. The rating was updated on 03 Sep 2026, reflecting changes in the company’s performance and valuation metrics. The reassessment comes amid the stock’s recent short-term underperformance and the evolving technical picture. What is the current rating for Sun Pharmaceutical Industries Ltd following this update?

Conclusion: A Stock Balancing Valuation, Performance, and Technical Signals

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation discount to its sector, with strong medium-term returns but recent short-term weakness. The moving average configuration suggests the stock is navigating a technical consolidation phase, supported by its position above the 200-day moving average but challenged by resistance at shorter-term averages. Sector results remain mixed, reflecting broader industry challenges. The recent rating reassessment from a previous Buy invites the question — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today